All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials

International Journal of Antimicrobial Agents

Volumn 41, Issue 5, 2013, Pages 463-467

  McGovern, Paul C ^a   Wible, Michele ^a   El Tahtawy, Ahmed ^a   Biswas, Pinaki ^a   Meyer, R Daniel ^a  

^a PFIZER INC   (United States)

Author keywords

All cause; Glycylcycline; Meta analysis; Mortality; Patient level data; Tigecycline

Indexed keywords

TIGECYCLINE;

ARTICLE; BACTEREMIA; CAUSE OF DEATH; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL; VENTILATOR ASSOCIATED PNEUMONIA;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, VENTILATOR-ASSOCIATED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84876285875     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.01.020     Document Type: Article

References (17)

1. P. McGovern, M. Wible, El-Tahtawy, P. Biswas, and D. Meyer Mortality imbalance in the tigecycline phase 3 and 4 clinical trials Crit Care Med 38 Suppl 12 2010 [Abstract 302]
2. P. Prasad, J. Sun, R.L. Danner, and C. Natanson Excess deaths associated with tigecycline after approval based on noninferiority trials Clin Infect Dis 54 2012 1699 1709
3. E. Tasina, A.B. Haidich, S. Kokkali, and M. Arvanitidou Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis Lancet Infect Dis 11 2011 834 844
4. K.Z. Vardakas, P.I. Rafailidis, and M.E. Falagas Effectiveness and safety of tigecycline: focus on use for approved indications Clin Infect Dis 54 2012 1672 1674
5. D. Yahav, A. Lador, M. Paul, and L. Leibovici Efficacy and safety of tigecycline: a systematic review and meta-analysis J Antimicrob Chemother 66 2011 1963 1971
6. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
7. ®(tigecycline) for injection for intravenous use. Highlights of prescribing information. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2012. http://labeling.pfizer.com/ ShowLabeling.aspx?id=491 [accessed 08.02.13].
8. D. Gardiner, G. Dukart, A. Cooper, and T. Babinchak Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials Clin Infect Dis 50 2010 229 238
9. A.K. Meagher, J.A. Passarell, B.B. Cirincione, S.A. Van Wart, K. Liolios, and T. Babinchak Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections Antimicrob Agents Chemother 51 2007 1939 1945
10. S.M. Bhavnani, C.M. Rubino, P.G. Ambrose, T.J. Babinchak, J.M. Korth-Bradley, and G.L. Drusano Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections Antimicrob Agents Chemother 54 2010 1207 1212
11. A.T. Freire, V. Melnyk, M.J. Kim, O. Datsenko, O. Dzyublik, and F. Glumcher Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia Diagn Microbiol Infect Dis 68 2010 140 151
12. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. A Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem/cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013 [Epub ahead of print].
13. D. Iarikov, J. Alexander, J. Charles, L. Tracy, and S. Nambiar Analysis of an increase in all-cause mortality in tigecycline treated patients 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 17-20 September 2011, Chicago, IL 2011 ASM Press Washington, DC [Abstract K-1428]
14. Korth-Bradley JM, McGovern PC, Salageanu J, Matschke K, Plotka A, Pawlak S. Tigecycline does not prolong corrected QT intervals in healthy subjects. Antimicrob Agents Chemother. 2013.[Epub ahead of print].
15. S.G. Thompson Why sources of heterogeneity in meta-analysis should be investigated BMJ 309 1994 1351 1355
16. R.P. Wenzel Perspective: attributable mortality - the promise of better antimicrobial therapy J Infect Dis 178 1998 917 919
17. Infectious Diseases Society of America The 10 × '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020 Clin Infect Dis 50 2010 1081 1083